cd38 inhibitor and 5-amino-1mq synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases SLC25A51 decouples the mitochondrial NAD+/NADH
SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism Small Molecule CD38 Inhibitors: Synthesis of 8 Amino N1 inosine 5 monophosphate, Analogues and Early Structure Activity Relationship Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38: Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome PMC CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions PMC
Pay in 4 interest-free payments of $7.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20



